James George to Rituximab
This is a "connection" page, showing publications James George has written about Rituximab.
Connection Strength
3.406
-
Maintenance rituximab for relapsing thrombotic thrombocytopenic purpura: a case report. Transfusion. 2019 03; 59(3):921-926.
Score: 0.626
-
Rituximab for thrombotic thrombocytopenic purpura: lessons from the STAR trial. Transfusion. 2017 10; 57(10):2532-2538.
Score: 0.567
-
Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2016 06 16; 127(24):3092-4.
Score: 0.520
-
Treatment of Immune Thrombocytopenia in Adults: Version 2019. Mayo Clin Proc. 2019 11; 94(11):2161-2163.
Score: 0.167
-
Preventable deaths during initial episodes of acquired Thrombotic Thrombocytopenic Purpura: Past and future. Am J Hematol. 2019 09; 94(9):E242-E244.
Score: 0.163
-
Caplacizumab Therapy without Plasma Exchange for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2019 07 04; 381(1):92-94.
Score: 0.163
-
The remarkable diversity of thrombotic thrombocytopenic purpura: a perspective. Blood Adv. 2018 06 26; 2(12):1510-1516.
Score: 0.152
-
The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura. Blood. 2015 Mar 05; 125(10):1526-31.
Score: 0.119
-
Bone marrow necrosis discovered in a patient with suspected thrombotic thrombocytopenic purpura. Am J Hematol. 2015 Mar; 90(3):264-6.
Score: 0.117
-
Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features. Pediatr Blood Cancer. 2013 Oct; 60(10):1676-82.
Score: 0.107
-
Corticosteroids and rituximab as adjunctive treatments for thrombotic thrombocytopenic purpura. Am J Hematol. 2012 May; 87 Suppl 1:S88-91.
Score: 0.098
-
Sequence of treatments for adults with primary immune thrombocytopenia. Am J Hematol. 2012 May; 87 Suppl 1:S12-5.
Score: 0.098
-
Diagnostic and therapeutic challenges in the thrombotic thrombocytopenic purpura and hemolytic uremic syndromes. Hematology Am Soc Hematol Educ Program. 2012; 2012:604-9.
Score: 0.097
-
Thrombotic thrombocytopenic purpura: 2008 update. Cleve Clin J Med. 2008 May; 75(5):369-75.
Score: 0.075
-
Management of patients with refractory immune thrombocytopenic purpura. J Thromb Haemost. 2006 Aug; 4(8):1664-72.
Score: 0.066
-
Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders. J Clin Apher. 2006 Apr; 21(1):49-56.
Score: 0.065
-
Recent advances in the treatment of chronic refractory immune thrombocytopenic purpura. Int J Hematol. 2005 Feb; 81(2):119-25.
Score: 0.060
-
Thrombotic thrombocytopenic purpura: from the bench to the bedside, but not yet to the community. Ann Intern Med. 2003 Jan 21; 138(2):152-3.
Score: 0.052
-
Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab. Am J Hematol. 2020 04; 95(4):E76-E77.
Score: 0.042
-
Management of primary immune thrombocytopenia, 2012: a survey of oklahoma hematologists-oncologists. Am J Med Sci. 2014 Mar; 347(3):190-4.
Score: 0.028
-
Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, 1996 to 2011. Transfusion. 2012 Dec; 52(12):2525-32; quiz 2524.
Score: 0.025